Ausgabe 4/2019
Inhalt (14 Artikel)
Survivin rs9904341 polymorphism significantly increased the risk of cancer: evidence from an updated meta-analysis of case–control studies
Abdolkarim Moazeni-Roodi, Saeid Ghavami, Mohammad Hashemi
To what extent does the EQ-5D-3L correlate with the FACT-H&N of patients with oral cancer during the perioperative period?
Takayuki Aoki, Yoshihide Ota, Masashi Sasaki, Ken-ichi Aoyama, Takeshi Akiba, Yukari Shirasugi, Mariko Naito, Takeru Shiroiwa
Genetic association of promoter in GRP78 gene with nasopharyngeal carcinoma in a Chinese population
Rong Wang, Hai-Mei Qin, Li Qin, Jing-Xi Wei, Yu-Xia Wei, Jun-Li Wang
Prognostic impact of underlying lung disease in pulmonary wedge resection for lung cancer
Takeshi Kawaguchi, Noriyoshi Sawabata, Sachiko Miura, Norikazu Kawai, Motoaki Yasukawa, Takashi Tojo, Shigeki Taniguchi
Histologic transformation of non-small-cell lung cancer in brain metastases
Meng Jiang, Xiaolong Zhu, Xiao Han, Haiyan Jing, Tao Han, Qiang Li, Xiao Ding
Verification of the diagnostic strategy for anterior mediastinal tumors
Shuhei Hakiri, Koji Kawaguchi, Takayuki Fukui, Shota Nakamura, Naoki Ozeki, Shunsuke Mori, Masaki Goto, Kumiko Hashimoto, Toshinari Ito, Kohei Yokoi
The effects of intraoperative ICG fluorescence angiography in laparoscopic low anterior resection: a propensity score-matched study
Toshiaki Wada, Kenji Kawada, Nobuaki Hoshino, Susumu Inamoto, Mami Yoshitomi, Koya Hida, Yoshiharu Sakai
Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial
Akihiro Tomida, Keisuke Uehara, Kazuhiro Hiramatsu, Atsuyuki Maeda, Eiji Sakamoto, Yoshito Okada, Yasuhiro Kurumiya, Goro Nakayama, Masanao Nakamura, Toshisada Aiba, Masato Nagino
The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study
Aristotelis Bamias, Vasilios Karavasilis, Nikolaos Gavalas, Kimon Tzannis, Epaminontas Samantas, Gerasimos Aravantinos, Angelos Koutras, Ioannis Gkerzelis, Euthymios Kostouros, Konstantinos Koutsoukos, Flora Zagouri, George Fountzilas, Meletios-Athanasios Dimopoulos
Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites
Yoshiko Kawata, Kazunori Nagasaka, Yoko Matsumoto, Katsutoshi Oda, Michihiro Tanikawa, Kenbun Sone, Mayuyo Mori-Uchino, Tetsushi Tsuruga, Takahide Arimoto, Yutaka Osuga, Tomoyuki Fujii
Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer
Yasunori Yoshino, Ayumi Taguchi, Maki Takao, Tomoko Kashiyama, Akiko Furusawa, Masaya Uno, Satoshi Okada, Nao Kino, Toshiharu Yasugi
Body composition as a predictor of toxicity after treatment with eribulin for advanced soft tissue sarcoma
Hiroshi Kobayashi, Tomotake Okuma, Hiroyuki Oka, Koichi Okajima, Yuki Ishibashi, Liuzhe Zhang, Toshihide Hirai, Takahiro Ohki, Yusuke Tsuda, Masachika Ikegami, Ryoko Sawada, Yusuke Shinoda, Toru Akiyama, Hirotaka Kawano, Takahiro Goto, Sakae Tanaka
Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)
Shin Fujisawa, Yasunori Ueda, Kensuke Usuki, Hajime Kobayashi, Eisei Kondo, Noriko Doki, Takafumi Nakao, Yoshinobu Kanda, Nobuharu Kosugi, Hiroshi Kosugi, Takashi Kumagai, Hiroshi Harada, Masato Shikami, Yasuhiro Maeda, Toru Sakura, Koiti Inokuchi, Akio Saito, Yuichiro Nawa, Masahiro Ogasawara, Junji Nishida, Takeshi Kondo, Chikashi Yoshida, Hiroyuki Kuroda, Yoko Tabe, Yoshinobu Maeda, Kenji Imajo, Kensuke Kojima, Satoshi Morita, Sho Komukai, Atsushi Kawaguchi, Junichi Sakamoto, Shinya Kimura
Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer
Shuji Hiramoto, Tomoko Tamaki, Kengo Nagashima, Tetsuo Hori, Ayako Kikuchi, Akira Yoshioka, Akira Inoue